Elicio Therapeutics, Inc ( (ELTX) ) has released its Q3 earnings. Here is a breakdown of the information Elicio Therapeutics, Inc presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer patients with limited treatment options. In its latest earnings report, Elicio Therapeutics highlighted its ongoing efforts in advancing its product candidates, despite facing financial challenges. The company reported a net loss of $31.9 million for the nine months ended September 30, 2025, compared to a net loss of $37.9 million in the same period of 2024. The company’s cash and cash equivalents increased to $20.6 million as of September 30, 2025, up from $17.6 million at the end of 2024, primarily due to financing activities including a public offering and an at-the-market equity program. Elicio Therapeutics continues to focus on the development of its lead product candidate, ELI-002 7P, and other pipeline products, while seeking additional funding to support its operations. Looking ahead, the company plans to address its financial needs through various capital sources, including potential partnerships and collaborations, as it continues to pursue its strategic objectives in the biotechnology sector.